1
Country: China | Funding: $370M
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
2
Country: USA | Funding: $555.6M
CG Oncology develops oncolytic immunotherapies for patients with advanced bladder cancer. Its flagship drug Cretostimogen is an intravesically administered oncolytic immunotherapy with a dual mechanism of action. It selectively replicates and lyses bladder cancer cells. The rupture of cancer cells can then release tumor-derived antigens, along with GM-CSF, which can stimulate a systemic antitumor immune response involving the body's immune system. CG Oncology has a robust clinical trial program with a developed pipeline to study the safety and efficacy of Cretostimogen. It has received FSA Fast Track and Breakthrough Therapy designations from the FDA.
CG Oncology develops oncolytic immunotherapies for patients with advanced bladder cancer. Its flagship drug Cretostimogen is an intravesically administered oncolytic immunotherapy with a dual mechanism of action. It selectively replicates and lyses bladder cancer cells. The rupture of cancer cells can then release tumor-derived antigens, along with GM-CSF, which can stimulate a systemic antitumor immune response involving the body's immune system. CG Oncology has a robust clinical trial program with a developed pipeline to study the safety and efficacy of Cretostimogen. It has received FSA Fast Track and Breakthrough Therapy designations from the FDA.
3
Country: USA | Funding: $96M
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
4
Country: USA | Funding: $112.3M
Insight Molecular Diagnostics (iMDx) develops and provides diagnostic tests for oncology. The company is developing three genetic tests: blood tests for breast and lung cancer and a urine test for bladder cancer. iMDx has also developed a blood-based transplant monitoring test that quantifies the concentration of donor cell-free DNA (dd-cfDNA) after transplantation. The company partners with biotech research laboratories and supplies them with tests intended exclusively for research purposes in oncology and transplantation research projects.
Insight Molecular Diagnostics (iMDx) develops and provides diagnostic tests for oncology. The company is developing three genetic tests: blood tests for breast and lung cancer and a urine test for bladder cancer. iMDx has also developed a blood-based transplant monitoring test that quantifies the concentration of donor cell-free DNA (dd-cfDNA) after transplantation. The company partners with biotech research laboratories and supplies them with tests intended exclusively for research purposes in oncology and transplantation research projects.
5
Country: Israel | Funding: $83M
Nucleix is developing liquid biopsy technology for the early detection of cancer. Its first product - Bladder EpiCheck test is certified for the diagnosis of primary and recurrent bladder and upper urinary tract cancer. This in vitro diagnostic device detects DNA methylation patterns in urine associated with urothelial carcinoma. It is intended for use as non-invasive method for monitoring tumor recurrence in conjunction with standard diagnostic procedures. The test analyzes small, disease-specific changes in DNA methylation markers, enabling the detection of cancer. The test has demonstrated high sensitivity (91%) for high-grade tumors, which are important to detect because they are aggressive and, if not treated immediately, can progress to invasive cancer. The company is also developing Lung EpiCheck to detect lung cancer at an early stage in high-risk individuals using a simple blood test.
Nucleix is developing liquid biopsy technology for the early detection of cancer. Its first product - Bladder EpiCheck test is certified for the diagnosis of primary and recurrent bladder and upper urinary tract cancer. This in vitro diagnostic device detects DNA methylation patterns in urine associated with urothelial carcinoma. It is intended for use as non-invasive method for monitoring tumor recurrence in conjunction with standard diagnostic procedures. The test analyzes small, disease-specific changes in DNA methylation markers, enabling the detection of cancer. The test has demonstrated high sensitivity (91%) for high-grade tumors, which are important to detect because they are aggressive and, if not treated immediately, can progress to invasive cancer. The company is also developing Lung EpiCheck to detect lung cancer at an early stage in high-risk individuals using a simple blood test.
6
Country: France | Funding: €4.7M
VitaDX is developing a non-invasive, AI-based test for the early detection of bladder cancer. It is based on VisioCyt technology, which uses deep learning and computer vision algorithms to analyze and diagnose digital cytology specimens. The test can be performed using a simple urine sample or screening data (for asymptomatic, high-risk patients). The company also offers the VisioCyt Thyroid test for diagnosing thyroid cancer using fine-needle aspiration biopsy.
VitaDX is developing a non-invasive, AI-based test for the early detection of bladder cancer. It is based on VisioCyt technology, which uses deep learning and computer vision algorithms to analyze and diagnose digital cytology specimens. The test can be performed using a simple urine sample or screening data (for asymptomatic, high-risk patients). The company also offers the VisioCyt Thyroid test for diagnosing thyroid cancer using fine-needle aspiration biopsy.
7
Country: Denmark
Cystotech uses artificial intelligence to improve bladder cancer treatment. They develop applications for use during cystoscopy and focus on improving diagnostic efficiency and use less invasive treatment approaches. Cystotech's technology improves tumor grade assessment, allowing surgeons to perform resections to the correct depth during primary tumor resection. This will reduce the recurrence rate and, consequently, the number of surgical interventions.
Cystotech uses artificial intelligence to improve bladder cancer treatment. They develop applications for use during cystoscopy and focus on improving diagnostic efficiency and use less invasive treatment approaches. Cystotech's technology improves tumor grade assessment, allowing surgeons to perform resections to the correct depth during primary tumor resection. This will reduce the recurrence rate and, consequently, the number of surgical interventions.
